These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36868506)

  • 1. Associations of altered hepatic gene expression in American lifestyle-induced obesity syndrome diet-fed mice with metabolic changes during NAFLD development and progression.
    Iannone V; Lok J; Babu AF; Gómez-Gallego C; Willman RM; Koistinen VM; Klåvus A; Kettunen MI; Kårlund A; Schwab U; Hanhineva K; Kolehmainen M; El-Nezami H
    J Nutr Biochem; 2023 May; 115():109307. PubMed ID: 36868506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    Govaere O; Petersen SK; Martinez-Lopez N; Wouters J; Van Haele M; Mancina RM; Jamialahmadi O; Bilkei-Gorzo O; Lassen PB; Darlay R; Peltier J; Palmer JM; Younes R; Tiniakos D; Aithal GP; Allison M; Vacca M; Göransson M; Berlinguer-Palmini R; Clark JE; Drinnan MJ; Yki-Järvinen H; Dufour JF; Ekstedt M; Francque S; Petta S; Bugianesi E; Schattenberg JM; Day CP; Cordell HJ; Topal B; Clément K; Romeo S; Ratziu V; Roskams T; Daly AK; Anstee QM; Trost M; Härtlova A
    J Hepatol; 2022 May; 76(5):1001-1012. PubMed ID: 34942286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.
    Dowman JK; Hopkins LJ; Reynolds GM; Nikolaou N; Armstrong MJ; Shaw JC; Houlihan DD; Lalor PF; Tomlinson JW; Hübscher SG; Newsome PN
    Am J Pathol; 2014 May; 184(5):1550-61. PubMed ID: 24650559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice.
    Tan R; Li J; Liu L; Wu Q; Fan L; Ma N; Yu C; Lu H; Zhang X; Chen J; Gong L; Ren J
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
    Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
    J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY6D is crucial for lipid accumulation and inflammation in nonalcoholic fatty liver disease.
    Lee J; Kim H; Kang YW; Kim Y; Park MY; Song JH; Jo Y; Dao T; Ryu D; Lee J; Oh CM; Park S
    Exp Mol Med; 2023 Jul; 55(7):1479-1491. PubMed ID: 37394588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
    Kopec AK; Joshi N; Towery KL; Kassel KM; Sullivan BP; Flick MJ; Luyendyk JP
    J Pharmacol Exp Ther; 2014 Nov; 351(2):288-97. PubMed ID: 25138021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nordihydroguaiaretic Acid, a Lignan from
    Chan JKW; Bittner S; Bittner A; Atwal S; Shen WJ; Inayathullah M; Rajada J; Nicolls MR; Kraemer FB; Azhar S
    J Pharmacol Exp Ther; 2018 May; 365(2):281-290. PubMed ID: 29472517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vitro and in vivo study of a 4-herb formula on the management of diet-induced metabolic syndrome.
    Wat E; Wang Y; Chan K; Law HW; Koon CM; Lau KM; Leung PC; Yan C; Lau CBS
    Phytomedicine; 2018 Mar; 42():112-125. PubMed ID: 29655677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression.
    Cheng K; Song Z; Zhang H; Li S; Wang C; Zhang L; Wang T
    Med Mol Morphol; 2019 Dec; 52(4):187-197. PubMed ID: 30673851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xie Zhuo Tiao Zhi formula modulates intestinal microbiota and liver purine metabolism to suppress hepatic steatosis and pyroptosis in NAFLD therapy.
    Qiu J; Chen L; Zhang L; Xu F; Zhang C; Ren G; Chang K; He G; Du Z; Le Y; Yu Z; Li S; Liu Q; Dou X
    Phytomedicine; 2023 Dec; 121():155111. PubMed ID: 37804819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fish oil alleviated high-fat diet-induced non-alcoholic fatty liver disease via regulating hepatic lipids metabolism and metaflammation: a transcriptomic study.
    Yuan F; Wang H; Tian Y; Li Q; He L; Li N; Liu Z
    Lipids Health Dis; 2016 Feb; 15():20. PubMed ID: 26832365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (
    Wu M; Lo TH; Li L; Sun J; Deng C; Chan KY; Li X; Yeh ST; Lee JTH; Lui PPY; Xu A; Wong CM
    Elife; 2023 Aug; 12():. PubMed ID: 37580962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnane X receptor exacerbates nonalcoholic fatty liver disease accompanied by obesity- and inflammation-prone gut microbiome signature.
    Kim S; Choi S; Dutta M; Asubonteng JO; Polunas M; Goedken M; Gonzalez FJ; Cui JY; Gyamfi MA
    Biochem Pharmacol; 2021 Nov; 193():114698. PubMed ID: 34303710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.